Last reviewed 2026-04-20 · How we verify

DPPIV inhibitor -

Royal Devon and Exeter NHS Foundation Trust · Phase 1 active Small molecule Quality 10/100

DPPIV inhibitor - is a Small molecule drug developed by Royal Devon and Exeter NHS Foundation Trust. It is currently in Phase 1 development. Also known as: Vidagliptin.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DPPIV inhibitor -
Also known as	Vidagliptin
Sponsor	Royal Devon and Exeter NHS Foundation Trust
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Revascularization Procedure
Lower Extremity Complication
Treatment for Retinopathy

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DPPIV inhibitor - CI brief — competitive landscape report
DPPIV inhibitor - updates RSS · CI watch RSS
Royal Devon and Exeter NHS Foundation Trust portfolio CI

Frequently asked questions about DPPIV inhibitor -

What is DPPIV inhibitor -?

DPPIV inhibitor - is a Small molecule drug developed by Royal Devon and Exeter NHS Foundation Trust.

Who makes DPPIV inhibitor -?

DPPIV inhibitor - is developed by Royal Devon and Exeter NHS Foundation Trust (see full Royal Devon and Exeter NHS Foundation Trust pipeline at /company/royal-devon-and-exeter-nhs-foundation-trust).

Is DPPIV inhibitor - also known as anything else?

DPPIV inhibitor - is also known as Vidagliptin.

What development phase is DPPIV inhibitor - in?

DPPIV inhibitor - is in Phase 1.

What are the side effects of DPPIV inhibitor -?

Common side effects of DPPIV inhibitor - include Revascularization Procedure, Lower Extremity Complication, Treatment for Retinopathy.

Manufacturer: Royal Devon and Exeter NHS Foundation Trust — full pipeline
Also known as: Vidagliptin

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing